• Congruence Therapeutics

  Participated · Equity · Mar 2026

  Congruence Therapeutics is a clinical-stage biotechnology company that uses a computationally driven discovery engine, Revenir, to identify allosteric and cryptic pockets and generate novel small-molecule correctors. Its lead program, CGX-926, is advancing toward a Phase 1/1b study for MC4R-deficient genetic obesity, and the recent $39.5M financing is earmarked to support that trial. The company has built a pipeline of wholly owned programs spanning genetic obesity, GBA Parkinson’s Disease, and α1‑Antitrypsin Deficiency. Congruence also leverages its platform to support research collaborations with large pharmaceutical companies across oncology, metabolic disease, neurology, and immunology. The company is led by CEO Dr. Clarissa Desjardins and is based in Montreal.

• Jade Biosciences

  Participated · Equity · Oct 2024

  Jade Biosciences is developing therapies aimed at redefining the standard of care for autoimmune diseases. The company launched in July 2024 and its portfolio was engineered by Paragon Therapeutics. Jade has appointed Tom Frohlich as CEO and Hetal Kocinsky, M.D., as CMO to lead clinical and commercial strategy. The company also formed a Board of Directors led by Eric Dobmeier that includes industry veterans across science and business. Jade announced an expanded financing to accelerate clinical development and strengthen its balance sheet. The company is associated with Vancouver, BC and San Francisco. Jade Biosciences is developing transformative, potentially best-in-class therapies for inflammation and immunology indications, with a focus on autoimmune diseases. Its programs are preclinical and built from assets engineered by Paragon Therapeutics. The company plans to advance targeted therapies for indications with high unmet need using newly raised capital. Jade named Andrew King, D.V.M., Ph.D., as Chief Scientific Officer; he brings over 15 years of leadership across biotech and pharma and experience in discovery, nonclinical development, translational medicine, and clinical development strategy. Jade is the fourth company launched from Paragon’s assets and is headquartered in Waltham, MA.

• MBX Biosciences

  Participated · Series C · Aug 2024

  MBX Biosciences develops precision-engineered peptide therapies via its proprietary Precision Endocrine Peptide™ (PEP™) platform designed to extend time-action profiles, provide consistent tissue exposure, and enable less frequent dosing. Its lead candidate, MBX 2109, is a parathyroid hormone peptide prodrug currently in a Phase 2 trial for chronic hypoparathyroidism, with topline results expected in the third quarter of 2025. MBX 1416, aimed at post-bariatric hypoglycemia, is in a Phase 1 single- and multiple-ascending dose trial with topline data expected in the fourth quarter of 2024. The company also advances an obesity portfolio including MBX 4291, a long-acting GLP-1/GIP receptor co-agonist prodrug in IND-enabling studies, plus multiple discovery and preclinical candidates. MBX says proceeds from its recent financing will support operations into 2026 and fund progression of its clinical and early-stage programs. The company is based in Carmel, Indiana. MBX Biosciences is a clinical-stage biopharmaceutical company pioneering Precision Endocrine Peptide (PEP) therapeutic candidates for endocrine disorders. Its lead candidate, MBX 2109, is a long-acting parathyroid hormone peptide prodrug designed for once-weekly dosing and is in a Phase 1 trial for hypoparathyroidism; MBX 2109 received FDA Orphan Drug designation in July 2022. Proceeds from the financing will support continued clinical advancement of MBX 2109, the preclinical program MBX 1416, and discovery programs in endocrine diseases. The company positions its PEP platform to overcome limitations of traditional peptide therapeutics by delivering sustained activity and improved pharmaceutical properties. MBX says its goal is to simplify disease management and improve outcomes and quality of life for patients with endocrine disorders. MBX is based in Carmel, Indiana. MBX Biosciences is a biotechnology company creating therapies for rare endocrine diseases with a focus on peptide therapeutics. The company advances a preclinical pipeline of peptide candidates directed at clinically validated molecular targets. MBX's platform and drug candidates are built on medicinal expertise and chemical technologies invented at the Indiana University laboratory of Professor Richard DiMarchi, who is co-founder and chief scientific officer. The company intends to advance its candidates toward clinical investigation to address endocrine disorders with substantial unmet medical need. MBX's leadership team, including president and CEO Kent Hawryluk, previously collaborated on successful endocrine drugs such as Humalog and Forteo. The company is based in Carmel, Indiana and is supported by leading life-science investors including Frazier Healthcare Partners, OrbiMed, and New Enterprise Associates. MBX Biosciences develops therapeutics aimed at rare endocrine disorders that the company says represent substantial unmet medical need. The company is pursuing initial discovery research to identify drug candidates with potential life‑saving properties against these disorders. MBX was founded by Indiana University Bloomington Distinguished Professor Richard DiMarchi, IUPUI alumnus Kent Hawryluk, and Tim Knickerbocker, and maintains several ties with Indiana University. The startup has an agreement to support research at the DiMarchi Laboratory in Bloomington and is a sponsor of IU‑based research. MBX completed an initial $2.5 million financing to fund its early discovery work. The leadership team has prior experience pairing on Marcadia Biotech and MB2, both acquired by large pharma, which the company cites as part of its institutional expertise.

• Confo Therapeutics

  Participated · Series B · Jul 2024

  Confo Therapeutics employs a proprietary discovery platform using conformation-specific ConfoBodies® to stabilize GPCRs in functionally relevant states and discover small molecules and agonistic antibodies. The company is building a pipeline focused on metabolic and endocrine diseases, including programs directed at obesity and severe rare endocrine disorders. Confo plans to advance two wholly owned programs through Phase 1 and bring two additional programs to IND approval, with explicit efforts on molecules targeting GPR75 for obesity. The company emphasizes both small-molecule GPCR modulators and therapeutic antibodies, notably agonistic antibodies. Confo is headquartered in Ghent, Belgium. Its current financial position includes the recently closed EUR 60M Series B financing to accelerate its development pipeline. Confo Therapeutics develops ConfoBodyTM single-domain camelid antibodies that selectively stabilize G-protein coupled receptors (GPCRs) to enable drug discovery. The company is building a portfolio of first-in-class programs based on its Confo® technology. It operates both internal discovery programs and revenue-generating partnerships with pharma on non-competing GPCR targets. Confo Therapeutics has active collaborations with Lundbeck and Roche to apply its platform. The firm plans to use new capital to advance its pipeline of GPCR-modulating compounds toward clinical candidates. The company was co-founded in 2015 as a VUB–VIB spin-off and is based in Ghent, Belgium. Confo Therapeutics is an emerging drug-discovery company based in Ghent, Belgium, that uses its proprietary Confo® technology to discover new GPCR agonist compounds for the treatment of fibrosis. The company operates a Drug Discovery Center in Gent and a Target Discovery Center in Brussels. It is expanding the applicability of its Confo® platform, supported by recent grant awards. Financially, Confo Therapeutics has been awarded non-dilutive funding totaling roughly €2.6 million to support its discovery programs. Part of the funding will be allocated over a two-year VLAIO grant primarily to the Gent Drug Discovery Center, while the Innoviris award will support work at the Brussels Target Discovery Center. The company’s near-term plans, as described in the awards, focus on fibrosis compound discovery and broadening the Confo® technology’s use.

• Alterome Therapeutics

  Participated · Series B · Apr 2024

  Alterome leverages its Kraken structure-guided, machine-learning drug discovery platform to design mutation-selective and isoform-selective small-molecule therapies. Its preclinical pipeline features a covalent AKT1 E17K mutation-selective inhibitor and a KRAS isoform-selective inhibitor designed to address approximately 90% of KRAS mutations, including G12V and G12D. The company emphasizes precision approaches intended to target cancer cells over normal cells to increase inhibition of key drivers while improving safety. Alterome recently closed a $132 million Series B financing to advance multiple wholly owned programs. Proceeds will be used to support advancing lead programs into the clinic, with the AKT1 and KRAS programs expected to begin clinical testing within the next 12 months. The company is led by an experienced precision oncology R&D team and is based in San Diego. Alterome Therapeutics is a precision oncology biotech developing alteration-specific targeted therapies to treat cancer. The company designs its pipeline programs using an in-house computational chemistry platform called “The Kraken,” which provides atomic-level insights and predicts ligand activity and binding modes. Its current pipeline comprises three next-generation precision oncology programs that the company plans to advance with the new financing. Management emphasizes a blend of computational chemistry, medicinal chemistry, and translational biology to design highly selective therapeutics against validated oncogenic drivers. The company is led by founder, CEO and CSO Eric Murphy, Ph.D., and an R&D team with experience in developing marketed oncology small-molecule drugs. Financially, Alterome has raised nearly $100 million to date following the latest extension to its Series A. Alterome Therapeutics is a precision oncology biotechnology company focused on developing alteration-specific therapeutics that target high-value, validated oncogenic drivers. The company is building targeted, alteration-specific medicines intended to advance the precision oncology field and transform treatment paradigms for cancer patients. Leadership is headed by co-founder Eric Murphy, Ph.D., who will serve as chief executive and chief scientific officer, and co-founder Ryan Corcoran, M.D., Ph.D., who will serve on the board and scientific advisory board. The team emphasizes seasoned R&D leaders with a history of developing marketed oncology small-molecule drugs. Alterome positions its scientific approach to address validated oncogenic drivers and pursue precision-targeted cancer therapies.

No current team members are available.